hypothalamic pituitary hormones - male hormones 1

Part I – Introduction & Overview

Endocrine System

• A collection of glands that release hormones into the bloodstream.

• Functions include:

  • Regulation of growth & development

  • Homeostasis

  • Metabolism

  • Sexual maturity & reproduction

  • Pregnancy, parturition, lactation

  • Urine production

• Major glands:

  • Pituitary

  • Pineal

  • Thyroid

  • Parathyroid

  • Adrenal cortex & medulla

  • Pancreas (islets of Langerhans)

  • Ovaries or testes

What is a Hormone?

• Chemical messengers produced by cells, carried by blood, and detected by target cells with specific high-affinity receptors.

• Two main chemical classes:

1. Steroids

• Derived from cholesterol.

• Synthesized in:

  • Adrenal cortex

  • Testes

  • Ovaries

• Examples: cortisol, estradiol.

• Mechanism: enter cell, bind receptor, interact with DNA → slower genomic effects.

2. Peptides/Proteins

• Modified amino acids, short peptides, or proteins.

• Bind to membrane-bound receptors.

• Examples:

  • Amines: adrenaline, noradrenaline

  • Peptides: oxytocin, ADH

  • Proteins: growth hormone, insulin

  • Glycoproteins: FSH, TSH

Homeostasis & Feedback

• Successful compensation → homeostasis restored.

• Failure to compensate → pathophysiology, illness, death.

• Negative feedback is common: hormone inhibits its own production.

Hypothalamus-Pituitary Axis

Hypothalamus

• Links nervous and endocrine systems.

• Regulates:

  • Temperature

  • Blood osmolarity

  • Feeding

  • Stress response

• Controls pituitary secretions.

Pituitary Gland (Hypophysis)

• Located at base of brain, near optic nerve.

• Two lobes:

  1. Anterior lobe (adenohypophysis) – glandular tissue, secretes hormones under hypothalamic control.

  2. Posterior lobe (neurohypophysis) – neural tissue, stores/releases hormones made in hypothalamus.

Anterior Pituitary Cell Types

Pharmacology & Pathology of Pituitary

• Hypoactivity: hormone deficiency.

• Hyperactivity: hormone excess, often due to tumors.

• Failure of whole gland → loss of control over thyroid, adrenals, gonads.

Part II – Detailed Hormonal Axes

Hypothalamic-Pituitary-Gonadal (HPG) Axis

• Controls:

  • Spermatogenesis (male gamete production)

  • Testicular function

Key Hormones & Mechanisms

1. GnRH (Gonadotropin-Releasing Hormone)

   • Decapeptide from hypothalamus.

   • Binds Gαq-coupled receptors in anterior pituitary.

   • Stimulates gonadotrophs to release LH & FSH.

2. Luteinizing Hormone (LH)

   • Glycoprotein: α (92 aa) & β (115 aa) chains.

   • Binds Leydig cell receptors → ↑ testosterone synthesis.

3. Follicle-Stimulating Hormone (FSH)

   • Same α-chain as LH, unique β-chain.

   • Binds Sertoli cell receptors → stimulates:

     • Aromatase

     • Growth factors

     • Inhibin

     • Androgen-Binding Protein (ABP)

Crosstalk Between Testicular Cells

• Leydig cells: produce testosterone.

• Sertoli cells: convert testosterone → estradiol (via aromatase), produce growth factors.

• Estradiol and growth factors act back on Leydig cells.

Spermatogenesis Support

• FSH promotes:

  • ↑ Spermatogonia (diploid)

  • ↑ Spermatocytes (haploid after 1st meiosis)

  • ↑ Spermatids (immature haploid sperm)

  • ↑ Sperm motility & fertility potential.

Inhibins

• TGF-β family peptide hormones.

• Secreted by Sertoli cells.

• Inhibit FSH secretion by anterior pituitary.

• Decrease mRNA for αLH, αFSH, βFSH (but not βLH).

Growth Hormone (GH) Axis

Regulation

• GHRF (Growth Hormone-Releasing Factor) → ↑ cAMP → ↑ GH release.

• Somatostatin (GHRIF) → ↓ cAMP → ↓ GH release.

• Synthetic somatostatin analogs (e.g., octreotide) treat GH excess disorders.

GH Actions

• Primary target: liver (produces IGF-1).

• Also acts on bone, cartilage, muscle, kidneys.

• Metabolic: lipolysis, ↑ plasma glucose.

• Growth-promoting: ↑ amino acid uptake, protein synthesis.

• Receptor: JAK/STAT cytokine receptor superfamily.

GH Deficiency in Childhood

• Dwarfism – due to:

  • Genetic disruption of somatorelin (GHRF)

  • Pituitary tumor

• Treatment: somatorelin analogs (e.g., sermorelin, Geref®).

Prolactin

Hyperprolactinemia

• Causes: prolactin-secreting tumors, certain drugs (e.g., DA antagonists).

• Effects in females:

  • Amenorrhea (lack of menstrual cycles)

  • Galactorrhea (spontaneous milk secretion)

• Effects in males:

  • Hypogonadism, impotence

  • ↓ libido, ↓ sperm production

  • Gynecomastia (breast enlargement)

Treatment

• DA agonists (e.g., bromocriptine) → ↓ prolactin, treat galactorrhea/pituitary tumors.

Posterior Pituitary Hormones

Synthesis & Release

• Hormones made in hypothalamic neurons (paraventricular & supraoptic nuclei).

• Axons extend to posterior pituitary → release into blood.

• No hypothalamic releasing factors – release via neuronal depolarization & Ca²⁺-induced exocytosis.

1. Anti-Diuretic Hormone (ADH / Vasopressin)

• Nonapeptide (9 aa).

• Functions:

  • Vasoconstriction (V1 receptors)

  • ↑ water reabsorption in kidney → ↓ urine volume (V2 receptors)

  • Minor role in ACTH secretion (V3 receptors)

• Stimuli for release: ↑ plasma osmolarity, hypotension.

ADH Receptors & Pathways

• V2: Gs → adenylate cyclase → cAMP → inserts aquaporin-2 (AQP2) water channels in kidney collecting ducts.

• V1 & V3: Gq → phospholipase C → IP3 pathway.

2. Oxytocin

• Structure: differs from ADH by 2 amino acids.

• Functions:

  • Uterine contraction during labor

  • Milk ejection during nursing

• Stimuli for release:

  • ↑ Estrogen levels

  • Cervical/vaginal stretch at end of pregnancy

  • Suckling of breast → myoepithelial cell contraction

Unique Positive Feedback Loop

• More oxytocin released → stronger contractions/milk ejection → more oxytocin released until process complete.

Clinical Uses of Synthetic Oxytocin (Pitocin®)

• Induce labor

• Facilitate lactation

• Control postpartum hemorrhage

• Administered via injection or nasal spray (oral route ineffective due to GI degradation).

Summary of Hormone Actions & Controls

Key Concepts for Learning

• Negative feedback is predominant in endocrine regulation (except oxytocin’s positive feedback).

• HPG axis is critical for reproduction, involving crosstalk between Leydig & Sertoli cells.

• GH & prolactin imbalances have significant developmental & reproductive consequences.

• Posterior pituitary hormones are synthesized in hypothalamus and released directly into blood.

• Receptor specificity and signaling pathways (cAMP, JAK/STAT, IP3) determine hormone action

QUESTIONS:

Section 1: Single Best Answer Questions

Q1:

A patient presents with polyuria, polydipsia, and hypernatremia. MRI reveals a pituitary tumor affecting the posterior lobe. Which hormone deficiency is MOST likely responsible?
A) Growth hormone (GH)
B) Anti-diuretic hormone (ADH)
C) Thyroid-stimulating hormone (TSH)
D) Adrenocorticotropic hormone (ACTH)

Answer:

B - Anti-diuretic hormone (ADH)
Rationale: Posterior pituitary stores/releases ADH (vasopressin). ADH deficiency causes diabetes insipidus → impaired water reabsorption → polyuria, polydipsia, hypernatremia. GH, TSH, ACTH are anterior pituitary hormones.

Q2:

A 35-year-old woman with amenorrhea and galactorrhea is found to have elevated prolactin. Which drug class is LEAST likely to have caused this?
A) Dopamine antagonists (e.g., metoclopramide)
B) Dopamine agonists (e.g., bromocriptine)
C) Typical antipsychotics (e.g., haloperidol)
D) SSRIs (e.g., fluoxetine)

Answer:

B - Dopamine agonists
Rationale: Dopamine agonists (bromocriptine, cabergoline) LOWER prolactin by stimulating dopamine D2 receptors. All others can increase prolactin: dopamine antagonists block inhibitory control, antipsychotics have D2 antagonism, SSRIs may increase prolactin via serotonin pathways.

Q3:

Which hormone mechanism involves direct binding to intracellular receptors and genomic effects via DNA interaction?
A) Insulin
B) Adrenaline
C) Cortisol
D) Growth hormone

Answer:

C - Cortisol
Rationale: Cortisol is a steroid hormone derived from cholesterol that crosses cell membranes, binds intracellular receptors, and affects gene transcription (genomic effects). Insulin, adrenaline, and GH bind membrane receptors with faster, non-genomic signaling.

Q4:

During labor, a patient receives synthetic oxytocin (Pitocin®) to augment contractions. What is oxytocin's unique feedback mechanism?
A) Negative feedback inhibiting further release
B) No feedback regulation
C) Positive feedback amplifying release
D) Ultra-short loop feedback to hypothalamus

Answer:

C - Positive feedback amplifying release
Rationale: Oxytocin exhibits rare positive feedback: contractions → cervical stretching → more oxytocin → stronger contractions until delivery completes. Most endocrine systems use negative feedback. Oxytocin's positive loop continues until the stimulus ends (baby delivered).

Section 2: Extended Matching Questions

Theme: Pituitary Cell Types & Hormones

Options:
A) Somatotrophs
B) Lactotrophs
C) Thyrotrophs
D) Corticotrophs
E) Gonadotrophs

Q1:

Secrete prolactin, implicated in galactorrhea/amenorrhea

Answer:

B - Lactotrophs secrete prolactin.

Q2:

Most abundant anterior pituitary cell type (~50%)

Answer:

A - Somatotrophs (GH-secreting) are most numerous.

Q3:

Secrete ACTH, stimulate adrenal cortex

Answer:

D - Corticotrophs secrete ACTH.

Q4:

Least abundant cell type, secrete TSH

Answer:

C - Thyrotrophs are rarest, secrete TSH.

Theme: Hormone Receptor Signaling Pathways

Options:
A) Gs → adenylate cyclase → cAMP
B) Gq → phospholipase C → IP₃/DAG
C) JAK/STAT cytokine receptor
D) Intracellular receptor → DNA binding
E) Receptor tyrosine kinase

Q1:

ADH (vasopressin) action on V2 kidney receptors

Answer:

A - V2 receptors use Gs/cAMP pathway for water reabsorption.

Q2:

Growth hormone receptor mechanism

Answer:

C - GH uses JAK/STAT cytokine receptor family.

Q3:

Cortisol mechanism of action

Answer:

D - Steroid hormones bind intracellular receptors, affect gene transcription.

Q4:

ADH (vasopressin) action on V1 vascular receptors

Answer:

B - V1 receptors use Gq/IP₃ pathway for vasoconstriction.

Section 3: Complex Clinical Scenario - In-depth Analysis

Scenario: Mr. Thompson, 42, presents with fatigue, weight gain, cold intolerance, and constipation. He's also noticed decreased libido and erectile dysfunction. Blood tests show:

• TSH: 12.5 mIU/L (high)

• Free T4: 8 pmol/L (low)

• Prolactin: 1200 mIU/L (markedly elevated, normal <500)

• Testosterone: 8 nmol/L (low)

• LH: 2.5 IU/L (low-normal)

• FSH: 3.0 IU/L (low-normal)

MRI pituitary shows: 8mm pituitary macroadenoma

Q1:

Analyze this endocrine picture: What axis is primarily affected? Explain the hormone interrelationships and why multiple hormones are abnormal.

In-depth Answer:

PRIMARY PATHOLOGY: PITUITARY MACROADENOMA
The tumor is causing mass effect and disruption of multiple pituitary functions.

1. THYROID AXIS DYSFUNCTION (MOST PROMINENT)

• Primary finding: ↑TSH + ↓Free T4

• Interpretation: This is secondary/central hypothyroidism (pituitary origin), NOT primary thyroid disease

• Why TSH is high despite low T4:

  • In primary hypothyroidism: TSH is VERY high (often >20-50)

  • Here TSH is only mildly elevated (12.5) despite very low T4

  • This represents inadequate TSH response → the pituitary should be producing MUCH more TSH to stimulate the thyroid

  • The tumor is impairing thyrotroph function

  • The mildly elevated TSH may be due to:
    a) Bioinactive TSH (immunologically detectable but functionally impaired)
    b) Disrupted negative feedback sensitivity
    c) Tumor compression of pituitary stalk altering hypothalamic control

2. HYPERPROLACTINEMIA MECHANISM

• Prolactin: 1200 mIU/L (markedly elevated)

• Causes:

  1. Direct secretion: Prolactinoma (but tumor would typically be larger if causing this level)

  2. Stalk effect: Tumor compressing pituitary stalk → disrupts dopaminergic inhibition

     • Normally, hypothalamus secretes dopamine (prolactin-inhibiting factor, PIF) via tuberoinfundibular pathway

     • Dopamine reaches anterior pituitary via portal system, inhibits lactotrophs

     • Stalk compression impairs dopamine delivery → disinhibition → prolactin rises

     • This is "stalk effect hyperprolactinemia" - common with non-prolactin-secreting tumors

  3. Co-secretion: Some tumors secrete both prolactin and other hormones

3. HYPOGONADISM (TESTOSTERONE DEFICIENCY)

• Findings: ↓Testosterone (8 nmol/L) with inappropriately low/normal LH/FSH

• Interpretation: Secondary (hypogonadotropic) hypogonadism

• Mechanisms:

  1. Direct tumor compression: Impairs gonadotroph function → reduced LH/FSH

  2. Hyperprolactinemia effects: High prolactin directly suppresses:

     • GnRH pulsatility from hypothalamus

     • Gonadotroph responsiveness to GnRH

     • Testicular Leydig cell function

  3. Hypothyroidism contribution: Severe hypothyroidism can cause hypogonadism via multiple mechanisms

4. INTEGRATED PATHOPHYSIOLOGY:
The tumor is causing a combined pituitary hormone deficiency with hyperprolactinemia as a "red flag" for stalk compression. The pattern suggests:

• Anterior pituitary impairment: Low T4 with inadequate TSH response, low testosterone with inadequate LH/FSH response

• Posterior pituitary spared: No diabetes insipidus symptoms (polyuria/polydipsia) → ADH function intact

• Stalk compression: Elevated prolactin without massive tumor size suggests dopamine pathway disruption

5. FEEDBACK LOOP DISRUPTIONS:
Normal: Low T4 → hypothalamus (TRH) → pituitary (TSH↑) → thyroid (T4↑) → negative feedback
Here: Low T4 → pituitary can't mount adequate TSH response due to tumor damage

Normal: Low testosterone → hypothalamus (GnRH) → pituitary (LH/FSH↑) → testes (testosterone↑)
Here: Low testosterone with low/normal LH/FSH → pituitary-gonadal axis failure

Q2:

Develop a comprehensive management plan addressing diagnosis, acute treatment, hormone replacement, and monitoring.

In-depth Answer:

IMMEDIATE DIAGNOSTIC WORKUP:

1. Pituitary function complete panel:

   • Anterior: TSH, FT4, FT3, LH, FSH, testosterone, prolactin, ACTH, cortisol (AM), GH, IGF-1

   • Posterior: Sodium, plasma/urine osmolality if polyuric

2. Visual field testing: Tumor proximity to optic chiasm

3. Endocrine stimulation tests if needed:

   • Insulin tolerance test (assess ACTH/cortisol, GH reserve)

   • GnRH stimulation test (assess gonadotroph reserve)

4. Additional imaging: Consider PET if suspicious features

ACUTE MANAGEMENT PRIORITIES:

1. Thyroid Hormone Replacement - CAUTION:

• Start LOW dose levothyroxine: 25-50 mcg daily

• Why cautious:

  • Central hypothyroidism + possible adrenal insufficiency

  • Thyroid hormone increases cortisol metabolism

  • Rapid correction could precipitate adrenal crisis if ACTH/cortisol deficient

• Check cortisol first: If cortisol low, start hydrocortisone BEFORE levothyroxine

• Target: TSH not reliable in central hypothyroidism; aim FT4 mid-normal range

2. Testosterone Replacement - DEFER initially:

• Reason: Testosterone can worsen sleep apnea (if present), cause erythrocytosis

• Priority: Address thyroid and adrenal first

• If libido/ED primary concern: Consider PDE5 inhibitors first

• When to start: After thyroid/adrenal stable, if symptoms persist

• Choice: Transdermal gel (Androgel) preferred over injections initially (less erythrocytosis risk)

3. Hyperprolactinemia Management:

• Observation first: Stalk effect hyperprolactinemia may improve with tumor shrinkage

• If symptoms bothersome: Consider low-dose cabergoline 0.25mg twice weekly

• Monitor: Prolactin monthly, echocardiogram if long-term dopamine agonist use

4. Tumor-Specific Treatment:
Option A: Surgical resection (transsphenoidal)

• Indications: Visual field defects, apoplexy, hormone hypersecretion, size >1cm

• Benefits: May restore normal pituitary function, definitive tissue diagnosis

• Risks: New hormone deficiencies (15-20%), CSF leak, infection

Option B: Medical management with dopamine agonists

• For prolactinomas: First-line (shrinks 80-90% of macroprolactinomas)

• For non-prolactinomas: Less effective but may shrink some tumors

• This case: Given stalk effect pattern, surgery may be preferred for decompression

Option C: Radiation (if surgery contraindicated/incomplete)

• Delayed effect: Hormone control in months, tumor shrinkage in years

• Risk: New hormone deficiencies (50% at 10 years), optic neuropathy

Recommended: Given macroadenoma with mass effects → neurosurgery referral

HORMONE REPLACEMENT PROTOCOL:

1. Glucocorticoid FIRST (if deficient):

• Hydrocortisone: 15-20mg daily (10mg AM, 5mg lunch, 5mg afternoon)

• Stress dosing: Double for fever, triple for surgery

• Monitor: Symptoms, weight, BP, glucose

2. Thyroid hormone SECOND (after cortisol adequate):

• Levothyroxine: Start 25-50 mcg, increase by 25 mcg every 4-6 weeks

• Target: FT4 mid-normal range

• Never use TSH to guide dosing in central hypothyroidism

3. Sex steroids THIRD:

• Testosterone: Gel 50mg daily or injections 100mg weekly

• Monitor: Hematocrit, PSA (if >40), lipids, BMD

• For libido/ED: May need both testosterone + PDE5 inhibitor

4. Growth hormone (consider later):

• Wait: 6-12 months after other replacements stable

• Indications: Poor quality of life, abnormal body composition, dyslipidemia

• Dosing: Start 0.1-0.3 mg daily, titrate to IGF-1 mid-normal

• Monitor: Glucose, IGF-1, symptoms

MONITORING SCHEDULE:

Month 1:

• Weekly: BP, weight, symptoms

• End of month: Cortisol day curve, FT4, electrolytes

Month 3:

• Full pituitary panel

• MRI pituitary (post-op baseline if surgery done)

• Visual fields

Month 6 & annually:

• Complete endocrine panel

• MRI if residual tumor

• Bone density (DEXA) if on long-term testosterone

• Cardiovascular risk factors

PATIENT EDUCATION:

1. Steroid emergency card: Always carry, know stress dosing

2. Medication timing: Levothyroxine on empty stomach, separate from calcium/iron

3. Sick day rules: Double hydrocortisone for fever, seek help if vomiting

4. Tumor symptoms: Headache, vision changes, polyuria

5. Follow-up: Lifelong monitoring needed

SPECIAL CONSIDERATIONS:

• Pre-surgery: Must have stress-dose steroids during procedure

• Post-op: Monitor for diabetes insipidus (transient or permanent)

• Fertility: If desires fertility, may need gonadotropin therapy (hCG/FSH) rather than testosterone

• Quality of life: May benefit from GH replacement if deficient

DOCUMENTATION:

Diagnosis: Pituitary macroadenoma with secondary hypothyroidism, hypogonadism, hyperprolactinemia
Plan:
1. Neurosurgery referral for tumor resection
2. Start hydrocortisone 20mg daily (split dose)
3. After 1 week, start levothyroxine 25mcg daily
4. Hold testosterone initially, reassess after surgery
5. Refer ophthalmology for visual fields
6. Educate re: steroid emergency card, sick day rules
Follow-up: Endocrinology 2 weeks, neurosurgery 1 week

Section 4: Diabetes Insipidus vs SIADH - Differential Diagnosis

Scenario: Two patients present with hyponatremia:

• Patient A: 65-year-old post-transsphenoidal pituitary surgery, polyuria (4L/day), urine specific gravity 1.002, plasma Na⁺ 155 mmol/L

• Patient B: 70-year-old with small cell lung cancer, euvolemic, urine osmolality 550 mOsm/kg, plasma Na⁺ 125 mmol/L, urine Na⁺ 40 mmol/L

Q: Differentiate between diabetes insipidus (DI) and SIADH, including pathophysiology, diagnostic criteria, and management strategies for each patient.

In-depth Answer:

PATIENT A: CENTRAL DIABETES INSIPIDUS

Pathophysiology:

• Post-surgical ADH deficiency: Transsphenoidal surgery damages posterior pituitary/hypothalamic neurons

• ADH (vasopressin) role: Binds V2 receptors in collecting ducts → inserts aquaporin-2 water channels → water reabsorption

• Deficiency → inability to concentrate urine → dilute polyuria → water loss → hypernatremia

Diagnostic Findings Explained:

1. Polyuria: >3L/day (normal <2.5L)

2. Urine specific gravity 1.002: Very dilute (normal 1.010-1.030)

3. Hypernatremia (155): From pure water loss

4. Urine osmolality: Would be low (<300 mOsm/kg, often <100)

5. Plasma osmolality: High (>295 mOsm/kg)

Types of DI to Consider:

1. Central (neurogenic) DI: ADH deficiency (this patient)

2. Nephrogenic DI: Renal resistance to ADH (normal/high ADH)

3. Dipsogenic DI: Primary polydipsia (psychogenic/structural hypothalamic lesion)

Water Deprivation Test Pattern (if done):

• Central DI: Urine remains dilute despite dehydration, responds to desmopressin

• Nephrogenic DI: Urine remains dilute, NO response to desmopressin

• Primary polydipsia: Urine concentrates appropriately with dehydration

Management for Patient A:
Acute post-op phase (first 1-2 days):

• Monitor: Strict I/O, hourly urine output, Na⁺ q4-6h

• Fluid replacement: 0.45% saline or 5% dextrose based on Na⁺

• Desmopressin: Only if significant polyuria (>300mL/hr × 2 consecutive hours) AND hypernatremia

• Caution: May have triphasic response:

  1. Phase 1 (0-24h): DI from surgical shock

  2. Phase 2 (1-7 days): SIADH from ADH leakage from damaged neurons

  3. Phase 3: Permanent DI if >90% neurons destroyed

Chronic management:

1. Desmopressin (DDAVP):

   • Forms: Intranasal, oral, sublingual, injection

   • Dosing: Individualize to control polyuria without hyponatremia

   • Example: Desmopressin 0.1mg oral BD, titrate to urine output

2. Free water access: Must be allowed to drink to thirst

3. Monitoring: Daily weight, occasional Na⁺ checks, avoid over-treatment (hyponatremia)

4. Sick day rules: Continue desmopressin, drink to thirst

Education:

• "Your body doesn't conserve water properly"

• "Medication replaces the missing hormone"

• "Drink when thirsty, don't force fluids"

• "Watch for headache/nausea (over-treatment signs)"

PATIENT B: SIADH (Syndrome of Inappropriate ADH Secretion)

Pathophysiology:

• Ectopic ADH production: Small cell lung cancer secretes ADH-like peptides

• Excess ADH → inappropriate water reabsorption → dilutional hyponatremia

• Volume status: Euvolemic (differentiates from hypovolemic hyponatremia)

Diagnostic Findings Explained:

1. Hyponatremia (125): Dilutional from water retention

2. Urine osmolality 550: Inappropriately concentrated despite low plasma osmolality

3. Urine Na⁺ 40: >20 mmol/L indicates not volume-depleted

4. Clinical euvolemia: No edema, normal JVP

5. Excluded: Normal thyroid, adrenal, renal function (prerequisites for SIADH diagnosis)

SIADH Diagnostic Criteria (all must be present):

1. Serum osmolality <275 mOsm/kg

2. Urine osmolality >100 mOsm/kg (often > plasma)

3. Clinical euvolemia

4. Urine Na⁺ >20 mmol/L (with normal salt intake)

5. Normal thyroid, adrenal, renal function

6. No diuretic use

Management for Patient B:
Acute/severe hyponatremia (if neurological symptoms):

• 3% hypertonic saline: 150mL bolus, repeat until symptoms improve or Na⁺ rises 4-6 mmol/L

• Goal: Raise Na⁺ by 4-6 mmol/L in first 24h, not >10-12 mmol/L

• Risk: Osmotic demyelination if corrected too rapidly

Chronic/asymptomatic management:

1. Fluid restriction: 500-1000 mL/day (first-line)

2. Salt tablets: Increase solute intake to enhance water excretion

3. Demeclocycline: 300-600mg BD (blocks ADH action in kidney, 2nd line)

4. Vaptans (tolvaptan): ADH V2 receptor antagonists

   • Use: Moderate-severe SIADH, failed fluid restriction

   • Dosing: 15mg daily, titrate to Na⁺ response

   • Monitoring: Frequent Na⁺ checks initially (risk of over-correction)

   • Limitation: Cost, liver toxicity risk

Cancer-specific considerations:

1. Chemotherapy: May reduce ectopic ADH production

2. Monitor: Sodium weekly during treatment

3. Prognosis: SIADH often improves with tumor response

COMPARATIVE TABLE:

MONITORING PARAMETERS:
For DI: Daily weight, urine output, Na⁺ weekly initially
For SIADH: Strict I/O, daily weight, Na⁺ q6-12h initially

EDUCATION CONTRASTS:
DI: "Drink to thirst, don't limit fluids"
SIADH: "Limit fluids to X mL/day, measure all intake"

PHARMACY IMPLICATIONS:
Drugs causing DI:

• Lithium (nephrogenic DI)

• Demeclocycline (induces DI - used to treat SIADH!)

• Amphotericin B

• Foscarnet

Drugs causing SIADH:

• SSRIs/SNRIs

• Carbamazepine

• Cyclophosphamide

• Vinca alkaloids

• MDMA (ecstasy)

Section 5: Growth Hormone Disorders - Pediatric vs Adult

Scenario: Two patients present with growth concerns:

• Patient C: 8-year-old boy, height <3rd percentile, normal proportions, delayed bone age, normal intelligence. Parents both average height.

• Patient D: 45-year-old woman with acromegaly features: enlarged hands/feet, coarse facial features, new-onset diabetes, hypertension. Pituitary MRI shows 1.5cm adenoma.

Q: Compare and contrast GH deficiency in childhood vs GH excess in adulthood, including pathophysiology, clinical features, diagnostic approaches, and treatment strategies.

In-depth Answer:

PATIENT C: CHILDHOOD GH DEFICIENCY (GHD)

Pathophysiology:

• GH-IGF-1 axis disruption:

  • Hypothalamus: GHRH deficiency or insensitivity

  • Pituitary: Somatotroph deficiency/dysfunction

  • Liver: IGF-1 production impaired

• Causes:

  • Idiopathic: Most common (including genetic mutations)

  • Congenital: Structural abnormalities (septo-optic dysplasia)

  • Acquired: Tumor, trauma, infection, radiation

  • This case: Likely idiopathic isolated GHD

Clinical Features:

1. Growth failure: Height velocity <4cm/year, falling off growth curve

2. Proportionate short stature: Normal upper/lower segment ratio

3. Delayed bone age: >2 years behind chronological age

4. "Cherubic" appearance: Round face, frontal bossing, central adiposity

5. Hypoglycemia: Especially in neonates/young children (GH counter-regulatory)

6. Micropenis: In males (GH supports penile growth)

Diagnostic Approach:

1. Auxology: Accurate height measurements over time, growth velocity

2. Bone age X-ray: Left hand/wrist, assesses growth potential

3. GH stimulation tests:

   • Required: GH <7-10 ng/mL on TWO different tests

   • Agents: Insulin, arginine, clonidine, glucagon

   • Gold standard: Insulin tolerance test (assesses ACTH reserve simultaneously)

4. IGF-1 & IGFBP-3: Low for age

5. MRI pituitary: Rule out structural abnormalities

6. Other pituitary function: TSH, cortisol, LH/FSH (may have multiple deficiencies)

Treatment:
Recombinant human GH (somatropin):

• Dosing: 0.16-0.24 mg/kg/week divided daily injections

• Administration: Subcutaneous, bedtime (mimics physiological secretion)

• Duration: Until growth plate fusion (bone age 14-15 girls, 16-17 boys)

• Monitoring:

  • Height every 3-6 months

  • IGF-1 every 3-6 months (avoid over-replacement)

  • Bone age annually

  • Glucose, thyroid function (GH affects both)

• Response: Typically 8-13 cm gain in first year, then 6-8 cm/year

Prognosis:

• Final height: Often within target height range if treated early

• Adult transition: May need re-testing (30-70% have normal GH as adults)

• Adult GHD: Consider continuation if confirmed deficient (metabolic benefits)

PATIENT D: ADULT GH EXCESS (ACROMEGALY)

Pathophysiology:

• GH-secreting pituitary adenoma: >95% of cases

• Excess GH → increased IGF-1 from liver

• Both GH and IGF-1 mediate tissue effects

• This case: Macroadenoma (>1cm) with mass effects likely

Clinical Features (ACRONYM):
A - Arthralgia/Arthritis (GH stimulates synovial tissue)
C - Carpal tunnel syndrome (nerve entrapment from soft tissue growth)
R - Rough, oily skin; skin tags
O - Organomegaly (heart, thyroid, liver, kidneys)
M - Metabolic (diabetes, hypertension, dyslipidemia)
E - Enlargement (hands, feet, jaw, tongue)
G - Growth (coarse facial features, frontal bossing)
A - Apnea (sleep apnea from soft tissue upper airway obstruction)
L - Lactation (galactorrhea from stalk effect or co-secretion)
Y - Youthful appearance? (paradoxically, may look younger initially)

Specific features in Patient D:

• New-onset diabetes: GH causes insulin resistance

• Hypertension: 30-40% of acromegalics

• Cardiomyopathy: GH stimulates cardiac growth → concentric hypertrophy

Diagnostic Approach:

1. IGF-1: Age-adjusted (single best screening test)

2. Oral glucose tolerance test (OGTT):

   • Gold standard: Measure GH during 75g OGTT

   • Normal: GH suppresses to <1 μg/L

   • Acromegaly: GH fails to suppress (often paradoxically increases)

3. MRI pituitary: Localize tumor, assess size/extension

4. Visual fields: If suprasellar extension

5. Complications screening:

   • Cardiac: Echocardiogram (cardiomyopathy)

   • Metabolic: HbA1c, lipids

   • Sleep: Polysomnography (sleep apnea)

   • Colon: Colonoscopy (increased colon polyps/cancer risk)

   • Bone: DEXA scan (possible osteoporosis despite apparent bone growth)

Treatment Goals:

1. Normalize IGF-1 (age-adjusted)

2. Control tumor size

3. Preserve pituitary function

4. Manage comorbidities

Treatment Modalities:

1. Surgery (transsphenoidal) - FIRST LINE for macroadenomas:

• Cure rates: Microadenomas 80-90%, macroadenomas 40-60%

• Complications: New hormone deficiencies, CSF leak, meningitis

• This patient: Good surgical candidate with macroadenoma

2. Medical Therapy (if surgery contraindicated/incomplete):

• Somatostatin analogs (SSAs): Octreotide, lanreotide

  • Mechanism: Bind somatostatin receptors on tumor

  • Efficacy: Normalize IGF-1 in 50-70%

  • Administration: Monthly injections

  • Side effects: Gallstones, GI upset, glucose intolerance

• GH receptor antagonist: Pegvisomant

  • Mechanism: Blocks GH receptor → normalizes IGF-1 without lowering GH

  • Use: If SSAs fail

  • Monitoring: Liver enzymes (hepatotoxicity risk)

• Dopamine agonists: Cabergoline

  • Efficacy: Modest (10-20% normalize IGF-1)

  • Use: Mild disease or adjunct

  • Advantage: Oral administration

3. Radiation (if medical therapy fails):

• Conventional: Fractionated over 5-6 weeks

• Stereotactic (Gamma Knife): Single session, more precise

• Drawback: Slow effect (years), high rate of hypopituitarism

For Patient D:
Recommended approach:

1. Surgical resection (given macroadenoma, mass effects likely)

2. Post-op: Check IGF-1 at 12 weeks

3. If persistent: Start somatostatin analog

4. Comorbidity management:

   • Diabetes: Metformin/GLP-1 agonists preferred (GH causes insulin resistance)

   • Hypertension: ACEi/ARBs (may also have cardiomyopathy)

   • Sleep apnea: CPAP referral

   • Arthritis: NSAIDs with caution (GI/cardiovascular risks)

Monitoring:

• IGF-1: Every 3-6 months

• MRI pituitary: Yearly if residual tumor

• Complications: Annual echocardiogram, colonoscopy q3-5 years, sleep study if symptomatic

• Pituitary function: TSH, cortisol, gonadal hormones post-op

COMPARATIVE TABLE:

PHARMACY CONSIDERATIONS:
GH replacement:

• Storage: Refrigerated, reconstitution instructions

• Administration: Rotate injection sites, proper needle disposal

• Adherence: Critical for growth response

• Cost: £10,000-£20,000/year, often requires prior authorization

Acromegaly drugs:

• SSAs: Administer IM deep gluteal, rotate sites

• Pegvisomant: Daily SC injection, monitor LFTs monthly × 6, then quarterly

• Cabergoline: Titrate slowly, monitor echocardiogram if high cumulative dose (>3g)

QUALITY OF LIFE:
GHD children: Psychosocial support for short stature, school accommodations
Acromegaly adults: Often delayed diagnosis (5-10 years), facial changes affect body image, chronic pain from arthritis

Follow-up:
Patient C (pediatric GHD): Pediatric endocrinology every 3-4 months during treatment
Patient D (acromegaly): Multidisciplinary team (endocrinology, neurosurgery, ophthalmology, cardiology)